AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35079115
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin and bicalutamide
Trial: 32770693
Drug: Single-plane MFU-V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-plane MFU-V treatment (4 MHz/4.5 mm transducer)
Trial: 32770693
Drug: Dual-plane MFU-V
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-plane MFU-V treatment (4 MHz/4.5 mm and 7 MHz/3.0 mm transducer)
Trial: 35644803
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) with flow: 50 L/min and FIO2 of 1.0
Trial: 35644803
Drug: Ordinary supplemental
RxNorm normalized name: ordinary salt combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary supplemental oxygen via a nasal cannula (flow: 6 L/min)
Trial: 36111149
Drug: Ozone treatment
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone treatment
Trial: 36351727
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (ciprofloxacin and metronidazole) added to surgical drainage of perianal abscess
Trial: 34085779
Drug: subcutaneous Ig
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous Ig (IgPro20; Hizentra®)
Trial: 32785245
Drug: Acceptance Facilitating
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance Facilitating Intervention (AFI) - short video showing an example of blended therapy
Trial: 34687909
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment approaches (control group)
Trial: 34144145
Drug: Yoga (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga (12 weekly sessions)
Trial: 36047065
Drug: Taurine 3
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine 3 g, twice/day, orally for 12 weeks
Trial: 32440731
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (1.32×10^11 CFU live bacteria including Lactobacillus acidophilus, Lactobacillus rhamnosus GG, Bifidobacterium animalis, and Bifidobacterium longum daily)
Trial: 32400356
Drug: Praziquantel mass
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel mass drug administration (MDA)
Trial: 32598751
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day, Clarithromycin 500 mg 2 times a day)
Trial: 32598751
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy with bismuth (Omeprazole 20 mg 2 times a day, Tetracycline 500 mg 4 times a day, Metronidazole 500 mg 3 times a day, Bismuth subcitrate potassium 120 mg 4 times a day)
Trial: 32598751
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy without bismuth (Omeprazole 20 mg 2 times a day, Amoxicillin 1000 mg 2 times a day, Clarithromycin 500 mg 2 times a day, Metronidazole 500 mg 2 times a day)
Trial: 35187781
Drug: BBL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBL treatment and intradermal injection of BTX
Trial: 35187781
Drug: BBL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBL treatment and intradermal injection of normal saline
Trial: 33857940
Drug: Endotoxin Adsorbent
RxNorm normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin Adsorbent (EA) therapy
Trial: 33111988
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate 2.5 mg chip (ChxC) as an adjunctive treatment to subgingival debridement
Trial: 33111988
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate 2.5 mg chip (ChxC)
Trial: 32379217
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg E4
Trial: 32907576
Drug: Navafenterol (50-2100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navafenterol (50-2100 μg)
Trial: 35043571
Drug: Alginate dressings
RxNorm normalized name: Restore Calcium Alginate Dressings 4x4.75"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate dressings with silver and high-G cellulose
Trial: 35997105
Drug: 4 units
RxNorm normalized name: Afrezza, 4 units inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 units of cryoprecipitate added to routine treatments
Trial: 35997105
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments without cryoprecipitate
Trial: 32531432
Drug: Enterovirus 71
RxNorm normalized name: ENTEROVIRUS 71
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enterovirus 71 (EV71) vaccine
Trial: 32077057
Drug: Intranasal glulisine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal glulisine
Trial: 34696733
Drug: Ultrasound-guided psoas
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided psoas compartment block (PCB) with bupivacaine 0.125% 6-8 ml/h
Trial: 32404742
Drug: Probiotics supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics supplemented with 100 mg bovine lactoferrin (bLf)
Trial: 35817738
Drug: HIFU and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU and ultrasound-guided percutaneous anhydrous ethanol injection with oxytocin
Trial: 35817738
Drug: HIFU and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU and ultrasound-guided percutaneous anhydrous ethanol injection (Control)
Trial: 33906853
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg two times per day for 16 weeks
Trial: 36154509
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD2, 5 mg/ml)
Trial: 36154509
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD1, 2 mg/ml)
Trial: 34425422
Drug: Self-management training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management training program (delivered by physical therapy doctoral students, 6-week duration)
Trial: 35775676
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine injection
Trial: 35775676
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bupivacaine injection)
Trial: 34849989
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg every 6 months for 12 months
Trial: 34535967
Drug: Denosumab 180
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab 180 mg every 6 months for 12 months
Trial: 36124755
Drug: Intensive Language‐Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive Language‐Action Therapy combined with standard care
Trial: 39358667
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg risankizumab
Trial: 35451681
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) syndrome differentiation
Trial: 34164939
Drug: Various mental
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various mental health interventions including Cognitive Behaviour Therapy, psychosocial approaches, group-based and family strengthening interventions, economic empowerment combined with family strengthening, group-based mindfulness, and community interventions.
Trial: 34164939
Drug: Traditional mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional mental health treatments and psychosocial interventions.
Trial: 33482888
Drug: TESI combined
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TESI combined with levobupivacaine added to oral pain medication
Trial: 33482888
Drug: Oral pain
RxNorm normalized name: Oral Pain Relief
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pain medication alone
Trial: 33482888
Drug: Transforaminal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal epidural injection with levobupivacaine and saline solution added to oral pain medication
Trial: 33482888
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral pain medication alone)
Trial: 35435194
Drug: Dexamethasone combined
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone combined with oxybuprocaine hydrochloride gel (G group)
Trial: 35507446
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) continuation
Trial: 35507446
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) withdrawal
Trial: 34109590
Drug: Rehabilitation training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation training on the basis of routine drug therapy
Trial: 36191597
Drug: Polycaprolactone injection
RxNorm normalized name: caprolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polycaprolactone injection
Trial: 36191597
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate gel injection
Trial: 33516674
Drug: Cognition-enhancing medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognition-enhancing medications
Trial: 36031273
Drug: Non-punitive performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-punitive performance feedback via weekly text messages about driving score and rank
Trial: 32031757
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for conversion disorder/functional neurological disorder (CD/FND)
Trial: 32031757
Drug: Comorbid depression
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comorbid depression treatment
Trial: 36253729
Drug: Standard volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard volume ESPB with 20 ml 0.25% bupivacaine
Trial: 36253729
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume ESPB with 40 ml 0.125% bupivacaine
Trial: 35410367
Drug: Orthoptic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthoptic therapy (at least 2 months) including anti-suppression, vergence, and accommodation training
Trial: 35410367
Drug: Orthoptic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthoptic therapy
Trial: 32407239
Drug: Combined histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined histamine H1/H2-receptor antagonists (Blockade)
Trial: 33959852
Drug: Active oral
RxNorm normalized name: Factive Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active oral orthotic (occlusal splint)
Trial: 35881051
Drug: Belumosudil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belumosudil (200 mg)
Trial: 35881051
Drug: Belumosudil (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belumosudil (1000 mg)
Trial: 33743659
Drug: Depot medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot medroxyprogesterone acetate (DMPA) injection
Trial: 34541744
Drug: 7-octave pure
RxNorm normalized name: Pure oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-octave pure tone sound therapy based on tinnitus characteristics
Trial: 34541744
Drug: 9 one-third
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 one-third octave pure tone sound therapy based on tinnitus characteristics
Trial: 32244296
Drug: Substrate Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substrate Reduction Therapy (SRT)
Trial: 33709889
Drug: Matching-Adjusted Indirect
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching-Adjusted Indirect Comparisons for hematological and oncological treatments
Trial: 32730561
Drug: Nonoperative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative management with antibiotics (n=370)
Trial: 35393360
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg indobufen two times daily
Trial: 34007245
Drug: Spiritual wellbeing
RxNorm normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spiritual wellbeing assessment using the Functional Assessment of Chronic Illness Therapy‐Spiritual Well‐Being Scale‐12
Trial: 32915892
Drug: Low-dose Combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Combination (2.5mg + 45mg for 2 weeks/5mg + 90mg for 10 weeks)
Trial: 33724890
Drug: Hypnotic analgesia
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic analgesia (H)
Trial: 33724890
Drug: Hypnotic analgesia
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic analgesia (H) + Virtual Reality distraction (VR)
Trial: 33724890
Drug: Hypnotic analgesia
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic analgesia (H) alone
Trial: 36101515
Drug: Micellar curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micellar curcumin (105 mg day-1) for 7 days
Trial: 36101515
Drug: Native curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native curcumin (105 mg day-1) for 7 days
Trial: 36209239
Drug: Apalutamide in
RxNorm normalized name: Product containing apalutamide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide in addition to ongoing androgen deprivation therapy (ADT)
Trial: 32593255
Drug: Plasma enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma enriched with platelets combined with traditional treatment
Trial: 32593255
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment alone
Trial: 35871950
Drug: OPF-105 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPF-105 (150 g dextrose, 60 g amino acids, 40 g fat, 1240 kcal per 2200 mL)
Trial: 35871950
Drug: BFI (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFI (150 g dextrose, 60 g amino acids, 840 kcal per 2000 mL)
Trial: 35871950
Drug: OPF-105 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPF-105 (multiple doses for 3 days)
Trial: 35871950
Drug: BFI (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFI (multiple doses for 3 days)
Trial: 33123091
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg oral iodine daily until delivery
Trial: 37395101
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care (CC)
Trial: 32413774
Drug: G‐Lok™ with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Lok™ with G‐Lok‐XL™ (fixed loop)
Trial: 32413774
Drug: ProCinch™ with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProCinch™ with G‐Lok‐XL™ (adjustable loop)
Trial: 32413774
Drug: G‐Lok™ (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Lok™ (control with socket tunnel)
Trial: 35861301
Drug: Low-dose calcineurin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calcineurin inhibitor (CNI) combined with sirolimus (SRL) after four weeks of standard regimen.
Trial: 33964852
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of 3 whole Gala apples (∼200 g edible parts)/d for 6 weeks
Trial: 33187518
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BJ) intake (140 mL, 12.8 mmol NO3‐)
Trial: 32622603
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CM without heat treatment)
Trial: 36472579
Drug: liraglutide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 3.0 mg/day
Trial: 36418131
Drug: Clinically assisted
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically assisted hydration (CAH) including parenteral fluids (dextrose saline 4% dextrose, 0.18% sodium chloride)
Trial: 32766705
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) with treatment as usual (TAU)
Trial: 35245661
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day allopurinol
Trial: 33274199
Drug: Tablet candy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet candy
Trial: 32966290
Drug: Praziquantel plus
RxNorm normalized name: moxidectin / praziquantel Oral Gel [Quest Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel plus Dihydroartemisinin-piperaquine combination
Trial: 32657958
Drug: Spanish language
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish language TAPS Tool (self-administered)
Trial: 32657958
Drug: Spanish language
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish language TAPS Tool (interviewer-administered)
Trial: 35612354
Drug: Developing Inclusive
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developing Inclusive Youth program (classroom-based, individually administered video tool with teacher-led discussions)
Trial: 33546968
Drug: Intraoperative fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative fluid (IOF) administration at a rate of 11.90 mL/kg/h (higher IOF rate)
Trial: 33546968
Drug: Intraoperative fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative fluid (IOF) administration at a higher rate
Trial: 33340263
Drug: Perampanel (2-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (2-12 mg/day)
Trial: 33340263
Drug: Perampanel (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (8 mg/day)
Trial: 32234295
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with Azacytidine (AZA) at 32 mg/m2 for 5 days every 28 days
Trial: 32234295
Drug: Preemptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive treatment with Azacytidine (AZA) at 75 mg/m2 for 5 or 7 days per cycle
Trial: 32234295
Drug: Donor lymphocyte
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor lymphocyte infusions (DLIs)
Trial: 32234295
Drug: Treatment suspension
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment suspension